Sponsor (lead underwriter): orient securities Underwriting Sponsor Co., Ltd.
Company profile:
Xishan technology focuses on surgical medical devices, especially in the field of minimally invasive surgical medical devices, mainly engaged in the research and development, production and sales of surgical power devices. The main products include surgical power supply equipment, consumables and accessories. At present, the products are mainly used in neurosurgery, otolaryngology, orthopedics, breast surgery and other clinical departments.
The controlling shareholder of Xishan Technology is Chongqing Xishan Investment Co., Ltd. As of the end of the reporting period, Xishan Investment directly holds 48.08% of the company's shares. As of May, 2023, Guo Yijun directly held 1638200 shares of the company, accounting for 4.12%; Guo Yijun and Li Daihong hold 65,438+000.00% shares of Xishan Investment, and Xishan Investment directly holds 65,438+0,965,438+065,438+0.43 million shares of the company, with a shareholding ratio of 48.08%; Guo Yijun is the managing partner of Tongxin Investment and Happiness. Tongxin Investment and Happiness hold 2,365,438+0.43 million shares and 6,465,438+0.00% shares respectively. To sum up, Guo Yijun and Li Daihong control 59.64% of the voting rights of the company (corresponding to 23,707,800 shares) and are the actual controllers of the company. During the reporting period, the actual controller of the company has not changed.
The prospectus issued by Xishan Science and Technology on May 18, 2023 shows that the company plans to raise 661234,500 yuan for the industrialization project of surgical power supply system, the construction project of R&D center, the information construction project, the upgrading project of marketing service network and supplementary working capital.
The announcement of Xishan Technology's initial public offering in science and technology innovation board on May 25th, 2023 shows that the estimated amount of funds raised by this fundraising project is 66,654,38+0,234, 500 yuan. According to the issue price of 135.80 yuan/share and the number of new shares issued of 13250367 million shares, if this issue is successful, it is estimated that the total amount of funds raised by the company will be 17993998 million yuan, after deducting about167871200,000 yuan.